Genetic & Molecular Testing policy updates
Track new and updated Genetic & Molecular Testing policies impacting reimbursement and clinical operations.
| Policy | Payer | Type | Specialty | Change | Effective |
|---|---|---|---|---|---|
| Germline genetic testing for hereditary cancer (BRCA1/2, PALB2, and multigene panels) | Blue Cross Blue Shield - Kansas | Clinical | Genetic & Molecular Testing | Modified | Feb 3, 2026 |
| Comprehensive Genomic Profiling for Selecting Targeted Cancer Therapies | Blue Cross Blue Shield - Kansas | Clinical | Genetic & Molecular Testing | Modified | Mar 26, 2024 |
| Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Non-Small-Cell Lung Cancer (EGFR, ALK, BRAF, ROS1, RET, MET, KRAS, NTRK) | Blue Cross Blue Shield - Kansas | Clinical | Genetic & Molecular Testing | Modified | Jan 22, 2024 |
| Carrier Screening for Genetic Diseases | Blue Cross Blue Shield - Kansas | Clinical | Genetic & Molecular Testing | Modified | Jan 1, 2024 |
| Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy) | Blue Cross Blue Shield - Kansas | Clinical | Genetic & Molecular Testing | Modified | Oct 2, 2023 |
| Gene Expression Profiling for Uveal Melanoma | Blue Cross Blue Shield - Kansas | Clinical | Genetic & Molecular Testing | Modified | May 9, 2022 |
| Genetic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Advanced Cancer | Blue Cross Blue Shield - Kansas | Clinical | Genetic & Molecular Testing | Modified | Mar 10, 2022 |
| Proteomic Testing for Systemic Therapy in Non-Small-Cell Lung Cancer | Blue Cross Blue Shield - Kansas | Clinical | Genetic & Molecular Testing | Modified | Apr 16, 2021 |
| Pharmacogenomic and Metabolite Markers for Patients Treated with Thiopurines | Blue Cross Blue Shield - Kansas | Clinical | Genetic & Molecular Testing | Modified | Apr 16, 2021 |
| KIF6 Trp719Arg genotyping (coverage policy) | Blue Cross Blue Shield - Kansas | Clinical | Genetic & Molecular Testing | Modified | Mar 10, 2011 |
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.
OpenPayer by Trek Health — Policy intelligence for billing and revenue cycle teams.
Coverage data is sourced from publicly available payer medical policy documents and updated as payers publish revisions. Read more about where our data comes from. Always consult the primary payer source for clinical decision-making.